Skip to main content
. Author manuscript; available in PMC: 2015 Aug 6.
Published in final edited form as: Gynecol Oncol. 2012 Aug 31;127(3):506–510. doi: 10.1016/j.ygyno.2012.08.037

Table 3. Dose escalation toxicity.

Adverse event Dose level
Level I Level II Level III Level IV
N= 5 N= 6 N= 3 N= 8
Grade of adverse event 1 2 3 4 1 2 3 4 5 1 2 3 4 1 2 3 4
Blood/bone marrow
 Hemoglobin 2 1 5 1* 1 1 3 1
 White blood cells 2 1 2 2 1* 2 3 3
 Neutrophils 2 1 1 1* 2 5
 Platelets 1*
Cardiac 1 1* 1
Coagulation
Constitutional 3 3 1 2 1 4 1
Dermatology 2 2 2 1 3
Endocrine 2
Gastrointestinal 2 2 2 1ˆ 1* 1 2 4 1
Genitourinary 1
Hemorrhage
Hepatobiliary 1
Infection 1 1 1* 1
Metabolic 2 1 2 1 2 @ 1* 2 1
Neurologic 1 2 1 2 1 1
Ocular/visual 2 1
Pain 1 1 1 1 3 1
Pulmonary 1* 1
Sexual 1

Dose Level II:

*

Colo-vesical fistula with pancytopenia, metabolic toxicity (hypocalcemia), hypotension, respiratory distress, and death occurring in a single patient.

Dose Level II:

ˆ

Grade 3 Nausea and vomiting and

@

hypokalemia were not DLTs in this study.